EA199900621A1 - Лечение рассеянного склероза путем приема внутрь или ингаляции сополимера-1 - Google Patents

Лечение рассеянного склероза путем приема внутрь или ингаляции сополимера-1

Info

Publication number
EA199900621A1
EA199900621A1 EA199900621A EA199900621A EA199900621A1 EA 199900621 A1 EA199900621 A1 EA 199900621A1 EA 199900621 A EA199900621 A EA 199900621A EA 199900621 A EA199900621 A EA 199900621A EA 199900621 A1 EA199900621 A1 EA 199900621A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
inhalation
copolymer
multiple sclerosis
reception inside
Prior art date
Application number
EA199900621A
Other languages
English (en)
Other versions
EA003128B1 (ru
Inventor
Рут Арнон
Адриан Гилберт
Милка Линенберг
Ривка Ривон-Крейтман
Михаэль Села
Двора Тейтельбаум
Original Assignee
Еда Ресёрч Энд Девелопмент Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Еда Ресёрч Энд Девелопмент Ко., Лтд. filed Critical Еда Ресёрч Энд Девелопмент Ко., Лтд.
Publication of EA199900621A1 publication Critical patent/EA199900621A1/ru
Publication of EA003128B1 publication Critical patent/EA003128B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Abstract

Настоящее изобретение относится к лечению множественного склероза путем приема внутрь или ингаляции сополимера-1 и фармацевтических составов, пригодных для такого лечения.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199900621A 1997-01-10 1998-01-12 Способ лечения рассеянного склероза и фармацевтический состав, содержащий сополимер-1 EA003128B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL11998997A IL119989A0 (en) 1997-01-10 1997-01-10 Pharmaceutical compositions for oral treatment of multiple sclerosis
PCT/US1998/000375 WO1998030227A1 (en) 1997-01-10 1998-01-12 Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1

Publications (2)

Publication Number Publication Date
EA199900621A1 true EA199900621A1 (ru) 2000-02-28
EA003128B1 EA003128B1 (ru) 2003-02-27

Family

ID=11069682

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199900621A EA003128B1 (ru) 1997-01-10 1998-01-12 Способ лечения рассеянного склероза и фармацевтический состав, содержащий сополимер-1

Country Status (19)

Country Link
EP (1) EP0975351B1 (ru)
JP (1) JP4216342B2 (ru)
KR (1) KR20000070058A (ru)
CN (1) CN100528222C (ru)
AT (1) ATE356608T1 (ru)
AU (1) AU737287B2 (ru)
BR (1) BRPI9807076B8 (ru)
CA (1) CA2277365C (ru)
CZ (1) CZ297983B6 (ru)
DE (1) DE69837324T2 (ru)
EA (1) EA003128B1 (ru)
HK (1) HK1025737A1 (ru)
HU (1) HU226612B1 (ru)
IL (2) IL119989A0 (ru)
NZ (1) NZ336690A (ru)
PL (1) PL193300B1 (ru)
SK (1) SK284029B6 (ru)
WO (1) WO1998030227A1 (ru)
ZA (1) ZA98214B (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
EP1098902A4 (en) 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES
IL140592A0 (en) * 1998-07-23 2002-02-10 Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
DE60041365D1 (de) * 1999-06-04 2009-02-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von Riluzol zur Behandlung Multipler Sklerose
NZ515685A (en) * 1999-06-04 2002-12-20 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Use of riluzole for the treatment of multiple sclerosis
ZA200206457B (en) 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
WO2001060392A1 (en) * 2000-02-18 2001-08-23 Yeda Research And Development Co., Ltd. At The Weizmann Institute Of Science Oral, nasal and pulmonary dosage formualtions of copolymer 1
EP1292279A4 (en) * 2000-06-05 2005-01-12 Teva Pharma USE OF GLATIRAMER ACETATE (COPOLYMER 1) FOR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
PT1459065E (pt) 2001-12-04 2010-10-11 Teva Pharma Processos para a medição da potência do acetato de glatirâmero
BR0307975A (pt) 2002-02-25 2005-01-11 Elan Pharm Inc Métodos para reduzir cronicamente a inflamação patológica em um paciente e para determinar a eficácia de um regime de administração crÈnica para tratar inflamação patológica em um indivìduo, composição e terapia combinada para tratamento crÈnico de inflamação patológica em um paciente e uso de um inibidor de alfa-4-integrina
SK50642005A3 (sk) * 2003-01-24 2006-02-02 Elan Pharmaceuticals, Inc. Kompozícia na liečenie demyelizačných ochorení a paralýzy podávaním remyelizačných látok
WO2006029411A2 (en) 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
CZ29723U1 (cs) 2009-08-20 2016-08-30 Yeda Research & Development Company, Ltd. Nízkofrekvenční terapie s glatiramer acetátem
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
NZ609938A (en) 2010-10-11 2015-11-27 Teva Pharma Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
CA2851510A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
NZ630421A (en) 2012-10-10 2018-07-27 Teva Pharma Biomarkers predictive for clinical response for glatiramer acetate
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN105884866B (zh) * 2015-01-26 2021-04-20 漳州未名博欣生物医药有限公司 格拉替雷的化学合成方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
CN107531750B (zh) * 2015-04-28 2021-03-16 深圳翰宇药业股份有限公司 多肽混合物高效液相色谱分析方法
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
WO2019002228A1 (en) 2017-06-26 2019-01-03 Institut Pasteur TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins

Also Published As

Publication number Publication date
AU737287B2 (en) 2001-08-16
PL193300B1 (pl) 2007-01-31
JP4216342B2 (ja) 2009-01-28
JP2001511121A (ja) 2001-08-07
BRPI9807076B8 (pt) 2021-05-25
CZ243799A3 (cs) 2000-06-14
CN100528222C (zh) 2009-08-19
CN1249690A (zh) 2000-04-05
EP0975351B1 (en) 2007-03-14
CA2277365C (en) 2011-04-12
HUP0001917A3 (en) 2001-12-28
EP0975351A4 (en) 2002-05-15
HU226612B1 (en) 2009-04-28
IL119989A0 (en) 1997-04-15
AU5819598A (en) 1998-08-03
EP0975351A1 (en) 2000-02-02
ZA98214B (en) 1999-08-11
WO1998030227A1 (en) 1998-07-16
CA2277365A1 (en) 1998-07-16
CZ297983B6 (cs) 2007-05-16
EA003128B1 (ru) 2003-02-27
BR9807076B1 (pt) 2013-10-29
DE69837324T2 (de) 2007-11-29
HK1025737A1 (en) 2000-11-24
IL130820A (en) 2007-03-08
SK284029B6 (sk) 2004-08-03
NZ336690A (en) 2001-05-25
BR9807076A (pt) 2000-05-02
SK93199A3 (en) 2000-11-07
DE69837324D1 (de) 2007-04-26
KR20000070058A (ko) 2000-11-25
PL334566A1 (en) 2000-03-13
HUP0001917A2 (hu) 2000-10-28
ATE356608T1 (de) 2007-04-15

Similar Documents

Publication Publication Date Title
EA199900621A1 (ru) Лечение рассеянного склероза путем приема внутрь или ингаляции сополимера-1
EA200000920A1 (ru) Производные бициклических гидроксамовых кислот
EA199901031A1 (ru) Производные бензимидазола
EA200000759A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA199800946A1 (ru) Концентрированный препарат антител
EA200000298A1 (ru) Агонисты простагландинов и их применение для лечения заболеваний костей
EA200400241A1 (ru) Направленные к мишени мультимерные контрастные вещества, основанные на пептидах
EA199900494A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200300082A1 (ru) S-ФТОРМЕТИЛОВЫЙ ЭФИР 6α, 9α-ДИФТОР-17α-[(2-ФУРАНИЛКАРБОНИЛ)ОКСИ]-11β-ГИДРОКСИ-16α-МЕТИЛ-3-ОКСО-АНДРОСТА-1,4-ДИЕН-17β КАРБОТИОКИСЛОТЫ В КАЧЕСТВЕ ПРОТИВОВОСПАЛИТЕЛЬНОГО АГЕНТА
EA199800357A1 (ru) Фармацевтические ангиостатические дипептидные композиции и способы их применения
YU149791A (sh) Mometason, furoat monohidrat i postupak za njegovo dobijanje
DK0705100T3 (da) Terapeutiske substituerede guanidiner
ES2191292T3 (es) Compuestos antivirales poliaromaticos.
EA199700253A1 (ru) Производные нодулиспоровой кислоты
EA199901013A1 (ru) Гели пролонгированного действия
ATE398630T1 (de) Zyklische conotoxin-peptide
EA200201138A1 (ru) Пептид, модулирующий рецептор тромбопоэтина
BR9707247A (pt) Diidrobenzofurano e compostos relacionados úteis como agentes antiinflamatórios
EA200100516A1 (ru) Производные 3,3-биарилпиперидина и 2,2-биарилморфолина
EA200000240A1 (ru) Соединения, препятствующие эффекту раннего превращения лекарственных средств
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
EA199800526A1 (ru) Производные бензимидазола и их применение для лечения вирусных инфекций
MY127474A (en) Naphthyl compounds, intermediates, compositions, and methods of use
EA200000092A1 (ru) Противоаллергические средства
EA200000875A1 (ru) Белки, взаимодействующие с каспазой-8

Legal Events

Date Code Title Description
MK4A Patent expired

Designated state(s): AM AZ BY KZ KG MD TJ TM RU